Frequency and features of myasthenia gravis developing after thymectomy

Area of Science:

• Neurology
• Immunology
• Thoracic Surgery

Background:

• Thymectomy is a standard treatment for myasthenia gravis (MG) with anti-acetylcholine receptor (AChR) antibodies.
• Myasthenia gravis onset after thymectomy for thymic tumors is uncommon but occurs.
• Understanding post-thymectomy onset (PostTx) MG is crucial for patient management.

Purpose of the Study:

• To determine the frequency of PostTx MG in patients undergoing thymectomy for thymic tumors.
• To investigate the clinical characteristics and potential predictors of PostTx MG.
• To compare PostTx MG with pre-thymectomy onset (PreTx) MG.

Main Methods:

• Retrospective review of clinical data from 158 patients with thymoma-associated MG.
• Identification of patients with PostTx MG.
• Analysis of pre-surgical anti-AChR antibody titers and electrophysiological testing results.

Main Results:

• 18 out of 158 patients (11%) were diagnosed with PostTx MG.
• Pre-thymectomy anti-AChR antibodies (82%) and electrophysiological abnormalities (50%) were common in PostTx MG.
• PostTx MG onset occurred early (<6 months) or late (≥6 months) after surgery, with late onset sometimes linked to thymoma recurrence.
• Clinical features and prognosis of PostTx MG were similar to PreTx MG.

Conclusions:

• PostTx MG accounts for approximately 11% of thymoma-associated MG cases.
• Pre-surgical anti-AChR antibody levels and electrophysiological tests may help predict PostTx MG development.
• No significant differences in clinical presentation or prognosis were found between PostTx MG and PreTx MG.